IL306042A - Stabilized formulations include bispecific antibodies against MUC16 and CD3 - Google Patents

Stabilized formulations include bispecific antibodies against MUC16 and CD3

Info

Publication number
IL306042A
IL306042A IL306042A IL30604223A IL306042A IL 306042 A IL306042 A IL 306042A IL 306042 A IL306042 A IL 306042A IL 30604223 A IL30604223 A IL 30604223A IL 306042 A IL306042 A IL 306042A
Authority
IL
Israel
Prior art keywords
muc16
bispecific antibodies
formulations containing
stabilized formulations
containing anti
Prior art date
Application number
IL306042A
Other languages
English (en)
Hebrew (he)
Inventor
Douglas Kamen
Teng-Chieh Yang
Xiaobin Xu
Haibo Qiu
Kenneth Graham
Original Assignee
Regeneron Pharma
Douglas Kamen
Yang Teng Chieh
Xiaobin Xu
Haibo Qiu
Kenneth Graham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Douglas Kamen, Yang Teng Chieh, Xiaobin Xu, Haibo Qiu, Kenneth Graham filed Critical Regeneron Pharma
Publication of IL306042A publication Critical patent/IL306042A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
IL306042A 2021-04-02 2022-04-01 Stabilized formulations include bispecific antibodies against MUC16 and CD3 IL306042A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170320P 2021-04-02 2021-04-02
US202263313927P 2022-02-25 2022-02-25
PCT/US2022/023122 WO2022212885A1 (en) 2021-04-02 2022-04-01 Stabilized formulations containing anti-muc16 x anti-cd3 bispecific antibodies

Publications (1)

Publication Number Publication Date
IL306042A true IL306042A (en) 2023-11-01

Family

ID=81579790

Family Applications (1)

Application Number Title Priority Date Filing Date
IL306042A IL306042A (en) 2021-04-02 2022-04-01 Stabilized formulations include bispecific antibodies against MUC16 and CD3

Country Status (13)

Country Link
US (1) US20220332849A1 (enExample)
EP (1) EP4313008A1 (enExample)
JP (1) JP2024513835A (enExample)
KR (1) KR20230165828A (enExample)
AU (1) AU2022246687A1 (enExample)
BR (1) BR112023019096A2 (enExample)
CA (1) CA3213546A1 (enExample)
CL (1) CL2023002922A1 (enExample)
CO (1) CO2023014918A2 (enExample)
IL (1) IL306042A (enExample)
MX (1) MX2023011469A (enExample)
TW (1) TW202304507A (enExample)
WO (1) WO2022212885A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
MX366337B (es) * 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
EP3411401A1 (en) * 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체

Also Published As

Publication number Publication date
WO2022212885A1 (en) 2022-10-06
CA3213546A1 (en) 2022-10-06
MX2023011469A (es) 2024-02-01
EP4313008A1 (en) 2024-02-07
CL2023002922A1 (es) 2024-03-08
JP2024513835A (ja) 2024-03-27
AU2022246687A1 (en) 2023-10-12
AU2022246687A9 (en) 2023-10-26
KR20230165828A (ko) 2023-12-05
US20220332849A1 (en) 2022-10-20
BR112023019096A2 (pt) 2023-12-05
CO2023014918A2 (es) 2023-11-20
TW202304507A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
IL307879A (en) High concentration bispecific antibody formulations
HUS2500032I1 (hu) Bispecifikus anti-BCMA X anti-CD3 antitestek és azok alkalmazásai
SI4076385T1 (sl) Formulacije protiteles anti-pd1
IL290512A (en) Pharmaceutical preparations containing bispecific antibodies directed against CD3 and CD20 and their uses
SG11202109822XA (en) Stabilized formulations containing anti-il-33 antibodies
EP4004054A4 (en) ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODIES AND ITS APPLICATION
IL286757A (en) Antibodies in specific
IL312700A (en) Stable formulations comprising a bispecific bcma/cd3 antibody
ZA202310292B (en) Anti-cldn4/anti-cd137 bispecific antibody
LT4157876T (lt) Anti-pd-1 antikūnai
ZA202206008B (en) Bispecific anti-ccl2 antibodies
IL320432A (en) Bispecific antibody compounds
IL318216A (en) Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
IL325692A (en) Stabilized formulations including bispecific antibodies against BCMA and CD3
HK40106470A (en) Stabilized formulations containing anti-muc16 x anti-cd3 bispecific antibodies
IL299152A (en) Stabilized formulations that include antibodies against CTLA-4
CA3297636A1 (en) Stabilized formulations containing anti-bcma x anti-cd3 bispecific antibodies
IL321509A (en) CD28/OX40 bispecific antibodies
CA3260186A1 (en) Formulations for Bispecific Antibodies: Anti-PD-L1/Anti-4-1BB
IL318297A (en) Anti-TL1A antibody formulations
HK40082040A (en) Stabilized formulations containing anti-cd20 x anti-cd3 bispecific antibodies
IL290690A (en) Optimization of formulations for dual-specificity antibodies
IL310275A (en) Antibody formulations
IL320411A (en) ANTI-CD3 antibodies
IL314840A (en) Stable Antibody Formulations